![Nicola Campbell](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Historique de carrière de Nicola Campbell
Anciens postes connus de Nicola Campbell
Sociétés | Poste | Début | Fin |
---|---|---|---|
Sofinnova Investments, Inc.
![]() Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Private Equity Investor | 01/01/2004 | 16/06/2008 |
Alvine Pharmaceuticals, Inc.
![]() Alvine Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Alvine Pharmaceuticals, Inc. develops and commercializes therapeutics for inflammatory diseases. It offers ALV003, tTG Inihibitors and HLA-DQ2 Blockers. The company was founded by Blair Stewart and Kevin R. Kaster in 2005 and is headquartered in San Carlos, CA. | Directeur/Membre du Conseil | - | - |
NextWave Pharmaceuticals, Inc.
![]() NextWave Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NextWave Pharmaceuticals, Inc. operates as a pharmaceutical company which focuses on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder. The company was founded by Mahendra G. Shah on September 25, 2006 and is headquartered in New York, NY. | Directeur/Membre du Conseil | - | - |
MARINUS PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | - | - |
Phenomix Corp.
![]() Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Directeur/Membre du Conseil | - | - |
Scale Management LLC
![]() Scale Management LLC Investment ManagersFinance Scale Management LLC (Scale Management) is a venture capital firm founded in 1995 by Kate D. Mitchell and Anchie Y. Kuo. The firm is headquartered in Foster City, California. | Corporate Officer/Principal | - | - |
Formation de Nicola Campbell
University of Guelph | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 7 |
Canada | 2 |
Opérationnelle
Director/Board Member | 4 |
Private Equity Investor | 1 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 5 |
Finance | 3 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
MARINUS PHARMACEUTICALS, INC. | Health Technology |
Entreprise privées | 5 |
---|---|
Sofinnova Investments, Inc.
![]() Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Finance |
Scale Management LLC
![]() Scale Management LLC Investment ManagersFinance Scale Management LLC (Scale Management) is a venture capital firm founded in 1995 by Kate D. Mitchell and Anchie Y. Kuo. The firm is headquartered in Foster City, California. | Finance |
Phenomix Corp.
![]() Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Health Technology |
NextWave Pharmaceuticals, Inc.
![]() NextWave Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NextWave Pharmaceuticals, Inc. operates as a pharmaceutical company which focuses on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder. The company was founded by Mahendra G. Shah on September 25, 2006 and is headquartered in New York, NY. | Health Technology |
Alvine Pharmaceuticals, Inc.
![]() Alvine Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Alvine Pharmaceuticals, Inc. develops and commercializes therapeutics for inflammatory diseases. It offers ALV003, tTG Inihibitors and HLA-DQ2 Blockers. The company was founded by Blair Stewart and Kevin R. Kaster in 2005 and is headquartered in San Carlos, CA. | Health Technology |
- Bourse
- Insiders
- Nicola Campbell
- Expérience